Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 1
1948 1
1961 2
1962 1
1963 4
1964 2
1965 1
1966 3
1967 2
1968 1
1969 3
1970 3
1971 4
1972 7
1973 11
1974 15
1975 17
1976 16
1977 22
1978 9
1979 13
1980 9
1981 11
1982 8
1983 14
1984 38
1985 33
1986 48
1987 93
1988 105
1989 142
1990 167
1991 202
1992 219
1993 255
1994 301
1995 275
1996 349
1997 425
1998 279
1999 313
2000 285
2001 284
2002 309
2003 323
2004 299
2005 308
2006 355
2007 420
2008 524
2009 560
2010 574
2011 590
2012 583
2013 639
2014 635
2015 572
2016 550
2017 551
2018 558
2019 275
2020 6
Text availability
Article attribute
Article type
Publication date

Search Results

11,540 results
Results by year
Filters applied: . Clear all
Page 1
Gadolinium Deposition in the Brain: Current Updates.
Choi JW and Moon WJ. Korean J Radiol 2019 - Review. PMID 30627029 Free PMC article.
Gadolinium-based contrast agents (GBCAs) are commonly used for enhancement in MR imaging and have long been considered safe when administered at recommended doses. ...
Gadolinium-based contrast agents (GBCAs) are commonly used for enhancement in MR imaging and have long been considered safe when admi
Gadolinium Retention: A Research Roadmap from the 2018 NIH/ACR/RSNA Workshop on Gadolinium Chelates.
McDonald RJ, et al. Radiology 2018. PMID 30204075 Free PMC article.
Despite evidence that macrocyclic GBCAs show less gadolinium retention than linear GBCAs, the safety implications of gadolinium retention are unknown. The mechanism and chemical forms of gadolinium retention, as well as the biologic activity and clinical importance of these retained gadolinium species, remain poorly understood and underscore the need for additional research. ...
Despite evidence that macrocyclic GBCAs show less gadolinium retention than linear GBCAs, the safety implications of gadolinium
Gadolinium deposition and the potential for toxicological sequelae - A literature review of issues surrounding gadolinium-based contrast agents.
Layne KA, et al. Br J Clin Pharmacol 2018 - Review. PMID 30032482 Free PMC article.
Every year, approximately 30 million magnetic resonance imaging scans are enhanced with gadolinium-based contrast agents (GBCAs) worldwide. ...We additionally evaluate the potential risk of toxicity from exposure to gadolinium in light of new guidance published by the US Food and Drug Administration and the European Medicines Agency, and discuss whether gadolinium deposition disease exists as a new diagnosis....
Every year, approximately 30 million magnetic resonance imaging scans are enhanced with gadolinium-based contrast agents (GBCAs) worl …
Evaluation of Gadolinium Deposition in the Brain After MR Arthrography.
Kralik SF, et al. AJR Am J Roentgenol 2018. PMID 30106613
OBJECTIVE: Although significant investigation has been done into the deposition of gadolinium in the brains of patients receiving IV gadolinium, there is little research concerning nonintravenous uses of gadolinium, specifically in conjunction with musculoskeletal MR arthrography. ...CONCLUSION: No association was found between intraarticular gadolinium administration for MR arthrography and detectable gadolinium deposition within the brain....
OBJECTIVE: Although significant investigation has been done into the deposition of gadolinium in the brains of patients receiving IV …
Safety of Gadolinium Administration in Children.
Elbeshlawi I and AbdelBaki MS. Pediatr Neurol 2018 - Review. PMID 30390954
Due to its high magnetic moment, gadolinium-based contrast agent made its way smoothly as the flagship paramagnetic contrast. ...This article elucidates the gadolinium-based contrast agent toxicity in the pediatric population based on the current available evidence....
Due to its high magnetic moment, gadolinium-based contrast agent made its way smoothly as the flagship paramagnetic contrast. ...This …
Gadolinium-based contrast agents: why nephrologists need to be concerned.
Leyba K and Wagner B. Curr Opin Nephrol Hypertens 2019 - Review. PMID 30531473 Free PMC article.
PURPOSE OF REVIEW: The hegemony of gadolinium-based contrast agent-induced adverse events stretches beyond those who have renal impairment. ...SUMMARY: Gadolinium-based contrast agents should be used with extreme caution....
PURPOSE OF REVIEW: The hegemony of gadolinium-based contrast agent-induced adverse events stretches beyond those who have renal impai …
Late Gadolinium Enhancement in Patients With Hypertrophic Cardiomyopathy and Preserved Systolic Function.
Mentias A, et al. J Am Coll Cardiol 2018 - Clinical Trial. PMID 30115224 Free article.
BACKGROUND: A high proportion of patients with hypertrophic cardiomyopathy (HCM) have evidence of late gadolinium enhancement (LGE) on cardiac magnetic resonance (CMR). ...
BACKGROUND: A high proportion of patients with hypertrophic cardiomyopathy (HCM) have evidence of late gadolinium enhancement (LGE) o …
Gadolinium-Based Contrast Agents in Kidney Disease: Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists.
Schieda N, et al. Can Assoc Radiol J 2018 - Review. PMID 29706252
Use of gadolinium-based contrast agents (GBCAs) in renal impairment is controversial, with physician and patient apprehension in acute kidney injury (AKI), chronic kidney disease (CKD), and dialysis because of concerns regarding nephrogenic systemic fibrosis (NSF). ...
Use of gadolinium-based contrast agents (GBCAs) in renal impairment is controversial, with physician and patient apprehension in acut …
Gadolinium and Multiple Sclerosis: Vessels, Barriers of the Brain, and Glymphatics.
Saade C, et al. AJNR Am J Neuroradiol 2018 - Review. PMID 30385472 Free article.
Gadolinium-enhanced MR imaging is currently the reference standard to detect active inflammatory lesions in MS. Knowledge of the patterns and mechanisms of contrast enhancement is vital to limit the radiologic differential diagnosis in the staging and evaluation of MS lesion activity. The aim of this review was the following: 1) to outline the pathophysiology of the effect of lymphocyte-driven inflammation in MS, 2) to describe the effects of gadolinium on the BBB and glymphatic system, and 3) to describe gadolinium enhancement patterns and artifacts that can mimic lesions in MS....
Gadolinium-enhanced MR imaging is currently the reference standard to detect active inflammatory lesions in MS. Knowledge of the patt
11,540 results
Jump to page
Feedback